- Home
- MTEN vs RNTX Comparison
MTEN vs RNTX Comparison
Compare MTEN & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEN
- RNTX
- Stock Information
- Founded
- MTEN 2015
- RNTX 2001
- Country
- MTEN China
- RNTX United States
- Employees
- MTEN N/A
- RNTX N/A
- Industry
- MTEN Building Products
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- MTEN Industrials
- RNTX Health Care
- Exchange
- MTEN Nasdaq
- RNTX Nasdaq
- Market Cap
- MTEN 29.3M
- RNTX 34.6M
- IPO Year
- MTEN 2024
- RNTX N/A
- Fundamental
- Price
- MTEN $2.92
- RNTX $1.75
- Analyst Decision
- MTEN
- RNTX Buy
- Analyst Count
- MTEN 0
- RNTX 2
- Target Price
- MTEN N/A
- RNTX $10.00
- AVG Volume (30 Days)
- MTEN 94.8K
- RNTX 164.4K
- Earning Date
- MTEN 10-01-2025
- RNTX 11-14-2025
- Dividend Yield
- MTEN N/A
- RNTX N/A
- EPS Growth
- MTEN N/A
- RNTX N/A
- EPS
- MTEN N/A
- RNTX N/A
- Revenue
- MTEN $10,735,337.00
- RNTX N/A
- Revenue This Year
- MTEN N/A
- RNTX N/A
- Revenue Next Year
- MTEN N/A
- RNTX N/A
- P/E Ratio
- MTEN N/A
- RNTX N/A
- Revenue Growth
- MTEN 16.63
- RNTX N/A
- 52 Week Low
- MTEN $2.40
- RNTX $1.04
- 52 Week High
- MTEN $26.03
- RNTX $4.16
- Technical
- Relative Strength Index (RSI)
- MTEN 25.93
- RNTX 71.18
- Support Level
- MTEN $2.40
- RNTX $1.30
- Resistance Level
- MTEN $5.80
- RNTX $1.75
- Average True Range (ATR)
- MTEN 0.81
- RNTX 0.16
- MACD
- MTEN 0.06
- RNTX 0.04
- Stochastic Oscillator
- MTEN 15.03
- RNTX 57.14
About MTEN Mingteng International Corporation Inc. Ordinary Shares
Mingteng International Corp Inc operates as an automotive mold developer and supplier in China. It provides an extensive product lineup including casting molds for turbocharger systems, braking systems, steering and differential systems, and other automotive system parts. Besides, it also produces molds for new energy electric vehicle motor drive systems, battery pack systems, and engineering hydraulic components, which are widely used in the automobile, construction machinery, and other manufacturing industries.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.